



(51) International Patent Classification:
A61K 31/65 (2006.01)

(21) International Application Number:
PCT/US2013/042037

(22) International Filing Date:
21 May 2013 (21.05.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/649,611 21 May 2012 (21.05.2012) US

(71) Applicants: **DCB-USA LLC** [US/US]; 1007 North Orange Street, 9th Floor, New Castle County, Wilmington, DE 19801 (US). **NATIONAL TAIWAN UNIVERSITY**; No. 1, Sec. 4, Roosevelt Road, Taipei, 10617 (TW).

(72) Inventor: **WANG, I-Jong**; No. 1, Changde St., Zhongzheng Dist., Taipei City, 10048 (TW).

(74) Agent: **KING, Anthony**; WPAT, P.C. Intellectual Property Attorneys, 1100 Quail Street, Suite 202, Newport Beach, CA 92660 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(54) Title: METHODS FOR DRUG SCREEN USING ZEBRAFISH MODEL AND THE COMPOUNDS SCREENED THEREFORM

(57) Abstract: The invention relates to a platform of using zebrafish in screening candidates for treating and/or preventing myopia and keratoconus disease. The invention is mainly based on that Lumican, one of several SLRPs, plays an important role in the regulation of fibrillogenesis or the genes affecting the size of eyeballs in zebrafish, in addition to playing an important role in clinical myopia. Therefore, the invention uses the established zebrafish model to further identify the drugs affecting the expression of lumican and collagen fibrillogenesis, and/or the regulation of eyeball size. These drugs are potential candidates for treating myopia and/or keratoconus disease.

